Home > Oncology > ESMO 2020 > Breast Cancer > Contradicting results for chemoimmunotherapy in metastatic TNBC

Contradicting results for chemoimmunotherapy in metastatic TNBC

ESMO 2020
Both IMpassion130 and IMpassion131 evaluated the effect of atezolizumab added to first-line chemotherapy in metastatic TNBC patients, but their results contradict. Recently, the phase 3 IMpassion130 trial showed a significant benefit in progression-free survival (PFS) for inoperable metastatic TNBC patients who were treated in first-line with the combination of atezolizumab and nab-paclitaxel (HR 0.80; P=0.002) [1]. This benefit was observed both in the intention-to-treat (ITT) population and in PD-L1 immune cell-positive patients. Median overall survival (OS) in the ITT population was 21.0 months for the atezolizumab-treated patients and 18.7 months in the placebo arm (HR 0.87; P=0.77); 3-year OS was 28% and 25%, respectively [2]. Median OS in the PD-L1-positive patients was 25.4 months in the atezolizumab arm versus 17.9 months with placebo (HR 0.67; not formally tested); 3-year OS was 36% and 22%, respectively. In the PD-L1-negative population...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on